Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 1;11(1):74-76.
doi: 10.1001/jamaoncol.2024.5364.

Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies

Michael V Gormally  1 , Monica F Chen  1 , Anne Marie Noronha  2 , Kristalla Panageas  1 , Maggie Reynolds  1 , Kaelyn Kohlasch  1 , Bryan Novak  1 , Tatiana Kee-Velez  1 , Nikeysha Clarke  1 , Michael Eubank  2 , Cynthia Chu  2 , Clare Wilhelm  1 , Amanda Blouin  3 , Chrisann Kyi  1 , Claire Friedman  1 , Charles M Rudin  1 , Mark G Kris  1 , Ronak Shah  2 , David Aggen  1 , Sandra D'Angelo  1 , Alexander N Shoushtari  1 , Michael F Berger  2   3   4 , Chaitanya Bandlamudi  2 , Christopher A Klebanoff  1   4 , Alexander Drilon  1 , Adam J Schoenfeld  1 , Mark T A Donoghue  2
Affiliations

Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies

Michael V Gormally et al. JAMA Oncol. .
No abstract available

Plain language summary

This case series evaluates whether human leukocyte antigen (HLA) genotype could be inferred from standard next-generation sequencing, comparing concordance with confirmatory whole-exome sequencing and assessing if this assisted in matching patients to clinical trials.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Gormally reported a patent for TCR therapeutics licensed to Affini-T Therapeutics. Dr Chen reported grants from Memorial Sloan Kettering Cancer Center (MSKCC) and personal fees from Monica F Chen Candel Therapeutics; stock in Nordisk, Doximity, Quest, and Figs. Dr Friedman reported financial support from Immunocore, Merck, Eli Lily, Marengo Therapeutics, Puma Biotechnology, Hotspot Therapeutics, AstraZeneca, and Bristol Myers Squibb. Dr Rudin reported personal fees from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Jazz, and Harpoon Therapeutics SAB; and licensing/royalties for DLL3-directed therapeutics. Dr Kris reported personal fees from AstraZeneca, Bristol Myers Squibb, Sanofi, Pfizer, Merus, Daicchi Sankyo; nonfinancial support from Genentech. Dr Shah is part owner of Krelytics LLC. Dr Aggen reported support from Adaptimmune, University of Illinois, Seattle Genetics, Bristol Myers Squibb, Century Therapeutics, Curio Science, and Astellas. Dr D'Angelo reported personal fees from Adaptimmune, GI Innovation, Incyte, Medendi, and Piper Sandler & Co. Dr Shoushtari reported personal fees from Bristol Myers Squibb, Immunocore, Erasca, and Novartis; grants from multiple institutions. Dr Berger reported personal fees from Eli Lilly, AstraZeneca, and Paige.ai; intellectual property rights (SOPHiA Genetics). Dr Klebanoff reported grants from NIH, MSKCC, and several other organizations; personal fees from multiple biotech companies; and patents for TCRs licensed to various companies. Dr Drilon reported personal fees from numerous pharmaceutical companies, royalties from Wolters Kluwer and UpToDate, and a patent for Selpercatinib-Osimertinib. Dr Schoenfeld reported personal fees from J&J, KSQ Therapeutics, BMS, Merck, AstraZeneca, and several other companies; grants from AffiniT, Achilles Therapeutics, GSK, Harpoon, and PACTpharma. No other disclosures were reported.

References

    1. Hassel JC, Piperno-Neumann S, Rutkowski P, et al. . Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023;389(24):2256-2266. doi:10.1056/NEJMoa2304753 - DOI - PMC - PubMed
    1. Hong DS, Van Tine BA, Biswas S, et al. . Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. Nat Med. 2023;29(1):104-114. doi:10.1038/s41591-022-02128-z - DOI - PMC - PubMed
    1. Shukla SA, Rooney MS, Rajasagi M, et al. . Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 2015;33(11):1152-1158. doi:10.1038/nbt.3344 - DOI - PMC - PubMed
    1. Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics. 2014;30(23):3310-3316. doi:10.1093/bioinformatics/btu548 - DOI - PMC - PubMed
    1. Lee H, Kingsford C. Kourami: graph-guided assembly for novel human leukocyte antigen allele discovery. Genome Biol. 2018;19(1):16. doi:10.1186/s13059-018-1388-2 - DOI - PMC - PubMed

LinkOut - more resources